Clinical Trials

Provision Center for Biomedical Research serves as an independent research site, consistently delivering excellence in patient care and study performance that meets research requirements and builds strong relationships with physician and sponsor partners.

Listed below are Active and Upcoming Clinical Trials. “Active” status means that Provision Center for Biomedical Research is actively involved in the trial, which may or may not be accepting new patients. Active status has two types: “Active: Open to Patient Enrollment” status is in the patient recruitment phase, where patients are welcome to enroll, provided they meet the study criteria; or “Active: Closed to Patient Enrollment”, where the study is still active in collecting data, but is closed to enrolling new patients. Should patients be interested in a trial that is closed to enrollment, they may inquire about other studies where they might qualify to participate.

If you would like more information on our clinical trials or want to learn more about enrollment, please CONTACT US

Active and Upcoming Clinical Trials

Listing Title
Description

An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. John Swisher, StatCare Medical Group
Listing Title
Listing Category
Description

A Phase 2, Double-blind, Randomized, Placebo controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF)

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. John Swisher, StatCare Medical Group
Listing Title
Listing Category
Description


Alzheimer’s Network for Treatment and Diagnostics. Observational study for patients who are being treated with Novel FDA approved therapies.

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. Monica Crane, Genesis Neuroscience Clinic
Listing Category
Description


A Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease.

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. Monica Crane, Genesis Neuroscience Clinic
Listing Category
Description

A phase 3, open-label, randomized study to assess the efficacy and safety of Camizestrant (AZD9833), a next generation. Oral selective estrogen receptor degrader, versus standard endocrine therapy, as adjusted treatment for patients with ER+/HER2- early breast cancer and an intermediate -high or high risk of recurrence who have completed definitive locoregional treatment and have no evidence or disease

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. Robert Schumaker, Tennessee Cancer Specialists
Listing Title
Listing Category
Description


A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer’s disease (EVOKE)

Study Status
Active: Closed to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. Monica Crane, Genesis Neuroscience Clinic
Listing Title
Listing Category
Description


A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer’s disease (EVOKE plus)

Study Status
Active: Closed to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. Monica Crane, Genesis Neuroscience Clinic
Listing Title
Listing Category
Description


PHINDER: Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. Eric Weaver, StatCare Medical Group
Listing Category
Description

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. Robert Schumaker, Tennessee Cancer Specialists
Listing Title
Description


A single-arm, open-label, Phase 2 study evaluating A single-arm, open-label, Phase 2 study evaluating by an On Body Delivery System, in combination with weekly carfilzomib and dexamethasone in adult participants with relapsed and/or refractory multiple myeloma (RRMM)

Study Status
Upcoming Trial
Trial Documentation:
Principal Investigator
Dr. Saji Eapen, Tennessee Cancer Specialists
Scroll to Top